The global next generation sequencing market size is expected to reach USD 31.26 billion by 2030, registering a CAGR of 21.12% from 2024 to 2030, according to a new report by Grand View Research, Inc. Next-generation Sequencing (NGS) is a parallel processing technique that can establish the sequence of nucleotides in a whole genome with scalability, ultra-high capacity, and fast speed. Furthermore, in the healthcare industry, NGS is gradually being incorporated into medical laboratory research, screening, and disease diagnoses. In personalized medicine, it has been frequently utilized to accelerate the drug research process.
Different potential sequencing methods such as RNA sequencing, whole-genome sequencing, and whole-exome and targeted sequencing amongst others are prominently used by researchers to get comprehensive sample analysis. When compared to the traditional Sanger sequencing technology, NGS is less expensive and provides higher throughput for DNA sequencing. The growing automation in the pre-sequencing protocols, post-sequencing protocols, and data analysis is also projected to have a positive impact on the NGS market. The utilization of novel platforms for the development of personalized medicine by medical analysis at a genetic level is also a significant factor, which is expected to enhance demand for NGS over the forecast period.
Besides, there are other significant growth trends that are being witnessed in the sequencing industry, such as the development of personalized medicine and companion diagnostics, growing advancements in cloud computing, and data integration. Furthermore, the easy availability of genomic and proteomic data has poised this market to exhibit potentially high-value avenues and opportunities for growth over the forecast period. The market growth is also being fueled by an increase in the global prevalence of cancer and the availability of sophisticated healthcare facilities. As per GLOBOCAN 2020, there have been 1,92,92,789 new cancer cases in 2020, with the number expected to rise to 2,88,87,940 by 2040. Such a substantial rise in the number of cancer cases is estimated to leverage cancer research which will eventually accelerate the NGS market growth.
The NGS diagnostic techniques have the potential to determine a virus's genomic sequence and aid scientists in their understanding of mutations. Furthermore, throughout the COVID-19 epidemic, governments across the globe have been collaborating with the corporate sector to introduce NGS technology to the market as a viable diagnostic tool. The US Food and Drug Administration granted Illumina Inc. a case of emergency use permit for the first COVID-19 diagnostic using the next-generation sequence technique in June 2020. The Illumina COVIDSeq Test for qualitative identification of SARS-CoV-2 RNA has been approved by the FDA. As a result, the usage of next-generation sequencing (NGS) technologies is projected to increase during the pandemic.
Request a free sample copy or view the report summary: Next Generation Sequencing Market Report
By application, the oncology segment held the largest revenue share of 27.31% in 2023. The segment growth is prominently attributed to increasing in the prevalence of cancer and advancements in sequencing technologies
The academic research segment is expected to grow lucratively over the forecast period due to an increase in application-based usage in these institutes and a rise in oncology research. In addition, advancements in R&D for therapeutics, oncology, and genomics research led to the growth of the market
In Asia Pacific, the market is expected to grow considerably during the forecast period owing to extensive developments in healthcare infrastructure, the positive approach of respective countries for adoption of advanced technologies, and the presence of key players
North America dominated the market with a share of 49.35% in 2023, due to the presence of high R&D investment, and availability of technologically advanced healthcare research framework, the development of WGS in the region is also expected to serve as a critical factor for the growth of the North America NGS market throughout the forecast period
Grand View Research has segmented the global next generation sequencing market on the basis of technology, product, application, workflow, end-use, and region:
Next Generation Sequencing Technology Outlook (Revenue, USD Million, 2018 - 2030)
Whole Exome Sequencing
Targeted Sequencing & Resequencing
Next Generation Sequencing Product Outlook (Revenue, USD Million, 2018 - 2030)
Next Generation Sequencing Application Outlook (Revenue, USD Million, 2018 - 2030)
Diagnostics and Screening
Newborn Genetic Screening
Single Gene Analysis
HLA Typing/Immune System Monitoring
Metagenomics, Epidemiology & Drug Development
Agrigenomics & Forensics
Next Generation Sequencing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
NGS Library Preparation Kits
Semi-automated Library Preparation
Automated Library Preparation
NGS Data Analysis
NGS Primary Data Analysis
NGS Secondary Data Analysis
NGS Tertiary Data Analysis
Next Generation Sequencing End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals & Clinics
Pharma & Biotech Entities
Next Generation Sequencing Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East & Africa
List of Key Players of Next Generation Sequencing Market
F. Hoffman-La Roche Ltd.
Thermo Fisher Scientific, Inc.
Bio-Rad Laboratories, Inc.
Oxford Nanopore Technologies
Perkin Elmer, Inc.
Eurofins GATC Biotech GmbH
GET A FREE SAMPLE
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
"The quality of research they have done for us has been excellent..."